作者
Zeinab Chahine,Steffen Abel,Thomas Hollin,Griffin L. Barnes,Jing-Gung Chung,Mary Elisabeth Daub,Isaline Renard,Jae‐Yeon Choi,Pratap Vydyam,Anasuya Pal,M. Alba-Argomaniz,Charles A.S. Banks,Jay S. Kirkwood,Anita Saraf,Isabel Camino,P. Castaneda,Mauro Cuevas,J. De Mercado-Arnanz,E. Fernandez-Alvaro,A. García-Pérez,Nuria Ibarz,S. Viera-Morilla,Jacques Prudhomme,Chester J. Joyner,Amy K. Bei,Laurence Florens,Choukri Ben Mamoun,Christopher D. Vanderwal,Karine G. Le Roch
摘要
We report the discovery of MED6-189, an analog of the kalihinol family of isocyanoterpene natural products that is effective against drug-sensitive and drug-resistant Plasmodium falciparum strains, blocking both asexual replication and sexual differentiation. In vivo studies using a humanized mouse model of malaria confirm strong efficacy of the compound in animals with no apparent hemolytic activity or toxicity. Complementary chemical, molecular, and genomics analyses revealed that MED6-189 targets the parasite apicoplast and acts by inhibiting lipid biogenesis and cellular trafficking. Genetic analyses revealed that a mutation in PfSec13 , which encodes a component of the parasite secretory machinery, reduced susceptibility to the drug. Its high potency, excellent therapeutic profile, and distinctive mode of action make MED6-189 an excellent addition to the antimalarial drug pipeline.